Vitrolife

Pre-Annual General Meeting Information • Oct 10, 2022

Press Release October 10, 2022 Gothenburg, Sweden

Election committee for Vitrolife AB (publ)

The following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2023:

Niels Jacobsen, appointed by William Demant Invest A/S Patrik Tigerschiöld, appointed by Bure Equity AB Erika Henriksson, appointed by EQT VIII Jón Sigurdsson, Chairman of the Board

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on April 27, 2022.

The Annual General Meeting of Vitrolife AB (publ) will be held on April 27, 2023 in Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board, Box 9080, 400 92 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Gothenburg, October 10, 2022 VITROLIFE AB (publ)

Contact:

Jón Sigurdsson, Chairman of the Board, email: jsigurdsson@ossur.com Patrik Tolf, CFO, phone +46 31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,150 people worldwide, headquartered in Gothenburg, Sweden.

___________________________________________________________________________________________________________________________________

Vitrolife Group's products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 am CET on October 10, 2022.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.